Printer Friendly

Articles from M2 Pharma (August 3, 2017)

1-19 out of 19 article(s)
Title Author Type Words
Amgen and Allergan submit biologics license application for ABP 980 to US FDA. 175
Aridis Pharmaceuticals Begins Patient Enrollment in International Study of Aerucin for Treatment of Acute Pneumonia. 236
Arjuna Natural Extracts Ltd gets positive response letter from US FDA for high-potency turmeric extract BCM-95 Curcumin. 240
Bolder BioTechnology Begins Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome. 237
Bukwang Pharmaceutical set to initiate phase III clinical trials of Lurasidone. 229
Caradigm Adds Insignia Health's Patient Activation Measure Survey into Its Care Management Solution. 295
China Biologic reports Q2 2017 unaudited financial results. Financial report 153
Compugen names new director and chairman of the board. 258
Emmes Wins USD 70m National Institutes of Health Contract for Pediatric Research. 244
Flex Pharma commences US phase two trial of Amyotrophic Lateral Sclerosis drug. 133
Haldex's board unanimously decides not to support Knorr-Bremse takeover offer. 497
Hansa Medical announces publication of results from Phase II studies of its lead candidate IdeS in The New England Journal of Medicine. 260
Hansa Medical's drug candidate IdeS sees positive results. 248
MedEquities announces dividend of USD0.21 per share for Q2 2017. 134
Millions of leprosy sufferers missing from official stats. 542
Pfenex elects Eef Schimmelpennink as CEO. 132
Phase II trial proves new injectable antiretroviral treatment to be as effective as standard oral therapy. 262
Symbiotix Biotherapies Names Mikhail as Executive Chairman of Its Board of Directors. 212
X4 Pharmaceuticals to Collaborate with Yale University to Study WHIM Syndrome. 404

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters